Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Randomized Phase IIa Study of Pertuzumab Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric or Gastroesophageal Junction Cancer
2011-002331-25Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pertuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and Gastric cancer (HER2-positive) (2 arms), sponsored by Roche. Primary endpoint: Minimum (trough) serum concentration (Cmin) for pertuzumab. Started Aug 2011; status: completed.
02
Drugs
pertuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaGastric cancer (HER2-positive)
Beyond the preview
Go deeper on 2011-002331-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002331-25.